This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | MicrobiomeTrials
← Back to trials NCT05896839
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-07-24Est. Completion: 2027-01-31
Enrollment target: 16 participantsLocations UC San Diego Moores Cancer Center, La Jolla, California, United States Keck Medicine of USC Koreatown, Los Angeles, California, United States Los Angeles General Medical Center, Los Angeles, California, United States USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States Sibley Memorial Hospital, Washington D.C., District of Columbia, United States UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida, United States University of Miami Sylvester Comprehensive Cancer Center at Sole Mia, North Miami, Florida, United States UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States Other microbiome trials you might be interested in Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Locally Recurrent Head and Neck Squamous Cell Carcinoma Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma Locally Recurrent Laryngeal Squamous Cell Carcinoma Locally Recurrent Oral Cavity Squamous Cell Carcinoma Locally Recurrent Oropharyngeal Squamous Cell Carcinoma Metastatic Head and Neck Squamous Cell Carcinoma Metastatic Hypopharyngeal Squamous Cell Carcinoma Metastatic Laryngeal Squamous Cell Carcinoma
Northwestern University, Chicago, Illinois, United States
Memorial Hospital East, Shiloh, Illinois, United States
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
NYU Langone Hospital - Long Island, Mineola, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States Metastatic Melanoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Melanoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Unresectable Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in tr…
Phoenix, United States Est. completion Jan 1, 2027
Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Cutaneous Melanoma Metastatic Mucosal Melanoma Metastatic Non-Cutaneous Melanoma Non-Cutaneous Melanoma Recurrent Cutaneous Melanoma Recurrent Mucosal Melanoma Recurrent Non-Cutaneous Melanoma
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physici…
Birmingham, United States Est. completion Sep 15, 2023